Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

9.10 EUR

0.00 %

5,643 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

0.00 %
+7.31 %
-26.91 %
-35.92 %
-38.10 %
+16.07 %
+149.32 %
+51.92 %
-98.50 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
65.84M EUR
Turnover
14.98K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
27.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 27.02.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Here is an interesting BBC news story regarding the current state of drug treatment for Alzheimer’s disease. bbc.com 'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests A major review has provoked a backlash after concluding the medicines provide too little...
4/17/2026, 7:10 AM
by Mikko Karvinen, Nexstim Oyj
56
Brainsway’s market value has already surpassed 600 million dollars. The market seems to highly value a profitably growing TMS company, but there are still less valued options available for interested buyers. Brainsway also released a press release yesterday stating that in the US...
4/16/2026, 9:50 AM
by Kyhnykeisari
30
In an episode of the Yle Areena series “Elossa” (Alive), 63-year-old Teresa shares her experiences with chronic neuropathic pain. She suffers from CRPS II pain (complex regional pain syndrome), which began after a surgical complication. Teresa has lived with continuous, widespread...
4/14/2026, 11:18 AM
by Kyhnykeisari
29
This is how many Brainlab sales partners from the EMEA region alone were pictured next to that stylish orange stool. Because every step matters I was thrilled to meet our sales partners from across Europe, the Middle East and Africa at our recent Brainlab EMEA Distributor Meeting...
4/19/2026, 3:00 PM
by Kyhnykeisari
28
An interesting Alz article from Christin Glorioso. Christin represents a newer way of thinking in Alz research, where prevention is also a goal. The article gives a quick glance at where we are with new drug therapies, and where we are with various device therapies (these are in ...
4/14/2026, 6:59 AM
by AccionHombre
18
I’m following the development and discussion of Alzheimer’s treatment with interest, and I can certainly say that drugs haven’t particularly helped my own close relative. The disease progresses, but that’s how it is with current treatments. That’s what makes it such a vicious disease...
4/17/2026, 10:39 AM
by AccionHombre
14
Medical XPRT NBS - Navigated Brain Stimulation System for Radiotherapy - Medical / Health... For patients undergoing radiotherapy for brain metastases, it is important to preserve quality of life after a course of therapy. As a non-invasive method, S... This could be a surprisingly...
yesterday
by Jatast
12
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.